Predict your next investment

PathoVax company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$2.75M | 3 yrs ago

About PathoVax

PathoVax is a biotech company developing a cost-effective human papillomavirus (HPV) vaccine machine with universal protection. PathoVax's pilot vaccine RGVax promises to provide protection against all 15 oncogenic HPVs and many others that cause various warts.

PathoVax Headquarter Location

1812 Ashland Ave Suite 100

Baltimore, Maryland, 21205,

United States

Latest PathoVax News

JHU startup PathoVax raises $2.75M, grows team - Baltimore

Oct 19, 2018

(Courtesy photo) PathoVax , a Johns Hopkins–born startup developing a vaccine for human papillomavirus virus (HPV), raised $2.75 million in new funding, cofounder Joshua Wang said. The equity funding round was led by United Heath Investments. The life science investment group is led by Dr. Alan Zhu, who is also director of the Baltimore-based Chinese Association for Medical Professionals , which counts 800 physicians as members and seeks to strengthen ties between medical communities in the U.S. and China. Private investors also participated. The startup is developing RGVax, a vaccine that is designed to protect against all cancer-causing forms of HPV. Vaccines against the are already available, but only protect against some strains of the disease. Wang and cofounder Weijie Poh began working on the technology while they were PhD students working in the lab of inventor Richard Roden at the Johns Hopkins University School of Medicine. The cofounders are alums of 43North, a Buffalo accelerator. Late last year, the company also received U.S. Small Business Innovation Research grant funding totaling about $2.3 million, Wang said. “Since then we’ve grown from a 2-person team to six employees and have been focused on pushing the vaccine toward first in human trials,” Wang said. The startup also recently moved into Johns Hopkins’ FastForward 1812 innovation hub. Along with targeting clinical trials in the first half of 2020, the company is also identifying other applications of the technology. The equity funding, Wang said, is aimed at “building the business side of the company.” The company is looking to bring on team members who are experienced in areas such as management and manufacturing.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PathoVax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PathoVax is included in 3 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.



5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

PathoVax Patents

PathoVax has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics



Immunology, Immune system, Vaccines, Clusters of differentiation, Infectious causes of cancer


Application Date


Grant Date


Related Topics

Immunology, Immune system, Vaccines, Clusters of differentiation, Infectious causes of cancer



CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.